What type of study is this?

This is a Case Report study (also classified as: Meta-Analysis).

What question did this study set out to answer?

To explore the relationship between anti-BCMA CAR T-cell therapy and the development of therapy-related myeloid neoplasm in multiple myeloma.

December 8, 2025Blood

High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma.

View Full Paper

Ask AI

Bookmark

Authors

DGDavid Gorlin

Discussion

Member takes

Overview

Case report reveals high-risk myeloid neoplasm post anti-BCMA CAR T-cell therapy in refractory multiple myeloma, indicating long-term treatment risks.

Key Points

To explore the relationship between anti-BCMA CAR T-cell therapy and the development of therapy-related myeloid neoplasm in multiple myeloma.
Case report of a female patient with refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy.
Analysis of clinical history following multiple lines of therapy, including autologous hematopoietic stem cell transplantation.
Cytogenetic analysis and next-generation sequencing performed to identify genetic abnormalities.
Patient achieved a complete response to anti-BCMA CAR T-cell therapy at 90 days post-infusion.
Developed severe cytopenias seven months post-CAR T-cell therapy.
Bone marrow biopsy revealed 12% myeloblasts and identified a TP53 missense mutation with a variant allele frequency of 85%.

Cite This Study

David Gorlin (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc1f https://doi.org/10.1182/blood-2025-7609

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma.

View Full Paper

Ask AI

Bookmark

Authors

DGDavid Gorlin

Discussion

Member takes

Overview

Case report reveals high-risk myeloid neoplasm post anti-BCMA CAR T-cell therapy in refractory multiple myeloma, indicating long-term treatment risks.

Key Points

To explore the relationship between anti-BCMA CAR T-cell therapy and the development of therapy-related myeloid neoplasm in multiple myeloma.
Case report of a female patient with refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy.
Analysis of clinical history following multiple lines of therapy, including autologous hematopoietic stem cell transplantation.
Cytogenetic analysis and next-generation sequencing performed to identify genetic abnormalities.
Patient achieved a complete response to anti-BCMA CAR T-cell therapy at 90 days post-infusion.
Developed severe cytopenias seven months post-CAR T-cell therapy.
Bone marrow biopsy revealed 12% myeloblasts and identified a TP53 missense mutation with a variant allele frequency of 85%.

Cite This Study

David Gorlin (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc1f https://doi.org/10.1182/blood-2025-7609

View Full Paper

Ask AI

Bookmark